Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study
International Journal of Urology · 2025
DOI: 10.1111/iju.70207 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Takuhisa Nukaya und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fujita-Health University School of Medicine, Toyoake, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Cytoreduction Surgical Procedures, Immune Checkpoint Inhibitors, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
We aimed to evaluate overall survival (OS) and determine the optimal timing of cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC) receiving immune checkpoint inhibitor (ICI)‐based therapy.
Methods
This retrospective study reviewed medical records of 447 patients with mRCC treated with ICI at multiple Japanese institutions between January 2018 and August 2023. From this cohort, 178 patients with lymph node or distant metastases received either cytoreductive nephrectomy (CN group; n = 72) or ICI therapy without cytoreductive nephrectomy (non‐CN group; n = 106) as first‐line treatment.
Results
Median progression‐free survival was 15.7 months, and median overall survival was 58.1 months. CN significantly improved OS, with the CN group's median OS not reached, compared to 29.6 months in the non‐CN group ( p = 0.01). Deferred CN also showed improved survival outcomes. Poor prognostic factors for immediate CN included International Metastatic Renal Cell Carcinoma Database Consortium poor risk, sarcomatoid differentiation, and a high neutrophil‐to‐lymphocyte ratio.
Conclusions
We developed a prognostic model to guide patient selection for CN, emphasizing the need for personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fujita-Health University School of Medicine, Toyoake, Japan.
- Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, Okayama University Graduate School of Medicine, Okayama, Japan.
- Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Urology, Tokyo Medical University, Tokyo, Japan.
ORCID-Profile: Takuhisa Nukaya, Kiyoshi Takahara, Wataru Fukuokaya, Keiichiro Mori, Takehiro Iwata, Kensuke Bekku, Ryoichi Maenosono, Yosuke Hirasawa, Motoo Araki, Yoshio Ohno
Zitieren
APA
Nukaya, T., Takahara, K., Toyoda, S., Inoki, L., Fukuokaya, W., Mori, K., Iwata, T., Bekku, K., Maenosono, R., Tsujino, T., Hirasawa, Y., Yanagisawa, T., Hashimoto, T., Komura, K., Araki, M., Fujita, K., Ohno, Y., & Shiroki, R. (2025). Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study. International Journal of Urology. https://doi.org/10.1111/iju.70207
Vancouver
Nukaya T, Takahara K, Toyoda S, Inoki L, Fukuokaya W, Mori K, et al. Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study. International Journal of Urology. 2025. doi:10.1111/iju.70207
BibTeX
@article{Nukaya2025,
author = {Nukaya, Takuhisa and Takahara, Kiyoshi and Toyoda, Shingo and Inoki, Lan and Fukuokaya, Wataru and Mori, Keiichiro and Iwata, Takehiro and Bekku, Kensuke and Maenosono, Ryoichi and Tsujino, Takuya and Hirasawa, Yosuke and Yanagisawa, Takafumi and Hashimoto, Takeshi and Komura, Kazumasa and Araki, Motoo and Fujita, Kazutoshi and Ohno, Yoshio and Shiroki, Ryoichi},
title = {Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70207}
}
EUVIMED